270 related articles for article (PubMed ID: 27121255)
1. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice.
Morrison MC; Mulder P; Salic K; Verheij J; Liang W; van Duyvenvoorde W; Menke A; Kooistra T; Kleemann R; Wielinga PY
Int J Obes (Lond); 2016 Sep; 40(9):1416-23. PubMed ID: 27121255
[TBL] [Abstract][Full Text] [Related]
2. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
[TBL] [Abstract][Full Text] [Related]
3. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
Nozaki Y; Fujita K; Wada K; Yoneda M; Kessoku T; Shinohara Y; Imajo K; Ogawa Y; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
BMC Gastroenterol; 2015 Apr; 15():42. PubMed ID: 25881230
[TBL] [Abstract][Full Text] [Related]
5. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
6. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
Bae CR; Hino J; Hosoda H; Miyazato M; Kangawa K
Life Sci; 2018 Sep; 209():349-356. PubMed ID: 30114411
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
8. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
9. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
11. Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis.
Yoshimine Y; Uto H; Kumagai K; Mawatari S; Arima S; Ibusuki R; Mera K; Nosaki T; Kanmura S; Numata M; Tamai T; Moriuchi A; Tsubouchi H; Ido A
Oncol Rep; 2015 Apr; 33(4):1657-66. PubMed ID: 25607821
[TBL] [Abstract][Full Text] [Related]
12. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
Miyazaki T; Shirakami Y; Kubota M; Ideta T; Kochi T; Sakai H; Tanaka T; Moriwaki H; Shimizu M
Oncotarget; 2016 Mar; 7(9):10448-58. PubMed ID: 26871288
[TBL] [Abstract][Full Text] [Related]
13. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.
Lo L; McLennan SV; Williams PF; Bonner J; Chowdhury S; McCaughan GW; Gorrell MD; Yue DK; Twigg SM
J Hepatol; 2011 Aug; 55(2):435-44. PubMed ID: 21184785
[TBL] [Abstract][Full Text] [Related]
14. The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
Schumacher JD; Kong B; Pan Y; Zhan L; Sun R; Aa J; Rizzolo D; Richardson JR; Chen A; Goedken M; Aleksunes LM; Laskin DL; Guo GL
Toxicol Appl Pharmacol; 2017 Sep; 330():1-8. PubMed ID: 28673684
[TBL] [Abstract][Full Text] [Related]
15. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
16. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
[TBL] [Abstract][Full Text] [Related]
17. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
18. Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity.
Mulder P; Morrison MC; Wielinga PY; van Duyvenvoorde W; Kooistra T; Kleemann R
Int J Obes (Lond); 2016 Apr; 40(4):675-84. PubMed ID: 26499443
[TBL] [Abstract][Full Text] [Related]
19. ADAMTS5 deficiency protects against non-alcoholic steatohepatitis in obesity.
Bauters D; Spincemaille P; Geys L; Cassiman D; Vermeersch P; Bedossa P; Scroyen I; Lijnen HR
Liver Int; 2016 Dec; 36(12):1848-1859. PubMed ID: 27254774
[TBL] [Abstract][Full Text] [Related]
20. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
